Kazia Therapeutics Stock Australian S.E.
Stocks
KZA
AU000000KZA9
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 226M 161M 138M 129M 118M 222M 15.37B 1.52B 595M 7.71B 604M 591M 25.48B | P/E 2026 * |
-11.7x | P/E 2027 * | -13.5x |
|---|---|---|---|---|---|
| Enterprise Value | 226M 161M 138M 129M 118M 222M 15.37B 1.52B 595M 7.71B 604M 591M 25.48B | EV / Sales 2026 * |
554x | EV / Sales 2027 * | 2,336x |
| Free-Float |
45.6% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +9.59% |
| Manager | Title | Age | Since |
|---|---|---|---|
John Friend
CEO | Chief Executive Officer | 56 | 01/05/2023 |
James Levine
DFI | Director of Finance/CFO | 55 | 01/06/2026 |
Sudha Rao
CTO | Chief Tech/Sci/R&D Officer | - | 15/04/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Steven Coffey
BRD | Director/Board Member | 65 | 06/11/2012 |
John Friend
CHM | Chairman | 56 | 11/08/2023 |
Ebru Davidson
BRD | Director/Board Member | - | 05/06/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +9.59% | -.--% | - | - | 164M | |
| +2.37% | +2.30% | +3.39% | +22.74% | 48.63B | |
| -0.62% | +4.58% | +487.47% | +624.71% | 46.3B | |
| +2.09% | +4.96% | +20.59% | +95.21% | 41.97B | |
| +3.85% | +3.13% | +29.60% | +16.50% | 39.51B | |
| -0.72% | -3.91% | +17.87% | +47.98% | 31.75B | |
| +3.04% | +1.89% | +31.62% | +143.62% | 16.48B | |
| +4.33% | +1.63% | - | - | 16.34B | |
| +1.44% | +1.52% | +4.22% | +31.00% | 14B | |
| +3.87% | +1.98% | +82.99% | +45.80% | 13.33B | |
| Average | +2.92% | +1.05% | +84.72% | +128.44% | 29.81B | |
| Weighted average by Cap. | +1.85% | +0.96% | +107.24% | +157.21% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 407K 290K 249K 232K 213K 401K 27.72M 2.74M 1.07M 13.9M 1.09M 1.07M 45.96M | 96.67K 68.82K 59.03K 55.12K 50.57K 95.1K 6.58M 650K 255K 3.3M 258K 253K 10.91M |
| Net income | -25.68M -18.29M -15.68M -14.65M -13.44M -25.27M -1.75B -173M -67.67M -877M -68.66M -67.16M -2.9B | -30.94M -22.03M -18.89M -17.64M -16.19M -30.44M -2.11B -208M -81.52M -1.06B -82.7M -80.9M -3.49B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
